Summary
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.
History
Ono Pharmaceutical Co., Ltd. (??????????, Ono Yakuhin K?gy? Kabushiki-gaisha) is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono (Japanese: ?????) started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. (Japanese: ??????????) in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Mission
Our mission is to contribute to the well-being of humanity through the discovery and commercialization of innovative and essential pharmaceutical products.
Vision
Our vision is to become the most trusted and scientifically advanced pharmaceutical company in the world.
Key Team
Katsuji Teranishi (Corp. Officer and Chief Officer of Sales, Mkt, Wholesales Mgt., Planning & Primary Care Bus. Div.)
Mr. Isao Ono (Exec. Officer, Director of Corp. Research & Director)
Mr. Hiroshi Ichikawa (Corp. Officer & Sr. Director of Medical External Affairs)
Mr. Toshihiro Tsujinaka (Sr. Exec. Officer, Exec. Director of Corp. Strategy & Planning and Director)
Mr. Toichi Takino Ph.D. (Sr. Exec. Officer, Exec. Director of Discovery & Research and Director)
Hiromu Habashita Ph.D. (Corp. Officer and Deputy Exec. Director of Discovery & Research Division)
Kiyoaki Idemitsu (Exec. Officer, Exec. Director of Clinical Devel. & Director)
Recognition and Awards
Ono Pharmaceutical has won numerous awards, including the Japan Pharmaceutical Industry's Industry Award, the Japan Society of Pharmaceutical Sciences and Technologies award, and the Ministry of Health's Contribution Award.
References
